MARKET

CAMP

CAMP

Camp4 Therapeutics Corp.
NASDAQ
4.150
+0.010
+0.24%
After Hours: 4.150 0 0.00% 19:30 08/28 EDT
OPEN
4.180
PREV CLOSE
4.140
HIGH
4.300
LOW
4.030
VOLUME
142.06K
TURNOVER
--
52 WEEK HIGH
7.75
52 WEEK LOW
1.410
MARKET CAP
260.43M
P/E (TTM)
-1.8890
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CAMP last week (0817-0821)?
Weekly Report · 5d ago
Major Insider Move at CAMP4 Therapeutics Shakes Up Investor Buzz
TipRanks · 08/22 02:02
CAMP4 Q2 Net Loss Widens; On Track To Advance CMP-002 Into Phase 1/2 Trial In Q4 2026
NASDAQ · 08/17 13:19
Weekly Report: what happened at CAMP last week (0810-0814)?
Weekly Report · 08/17 09:21
Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler
TipRanks · 08/16 13:27
CAMP4 Analyst Day, Strong Cash Runway and SYNGAP1 Trial Progress Drive Upward Price-Target Revision to $8 with Buy Rating
TipRanks · 08/14 20:25
CAMP4 Therapeutics Price Target Raised to $15.00/Share From $12.00 by Piper Sandler
Dow Jones · 08/14 16:33
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15
Benzinga · 08/14 16:22
More
About CAMP
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Webull offers Camp4 Therapeutics Corp. stock information, including NASDAQ: CAMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAMP stock methods without spending real money on the virtual paper trading platform.